✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals

Caplin Point Laboratories Ltd.

CAPLIPOINT

Market Cap
₹14,350 Cr.
P/E
27.85

Caplin Point Laboratories Ltd.

  • Caplin Point Lab
  • Gufic Biosciences
  • Gland Pharma
  • TJI Pharma - Small Cap
FAQs on Caplin Point Laboratories Ltd. Shareprice

Caplin Point Lab has given better returns compared to its competitors.
Caplin Point Lab has grown at ~38.88% over the last 4yrs while peers have grown at a median rate of -0.96%

Yes, Caplin Point Lab is expensive.
Latest PE of Caplin Point Lab is 27.85, while 3 year average PE is 21.52.
Also latest EV/EBITDA of Caplin Point Lab is 22.14 while 3yr average is 15.96.

View FAQ's On Business
Growth Table
  • Caplin Point Laboratories Ltd.
  • Gufic Biosciences
  • Gland Pharma
Balance Sheet
  • Caplin Point Laboratories Ltd.
  • Gufic Biosciences
  • Gland Pharma
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Caplin Point Laboratories Ltd.
  • Gufic Biosciences
  • Gland Pharma
Cash Flow
  • Caplin Point Laboratories Ltd.
  • Gufic Biosciences
  • Gland Pharma
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Caplin Point Laboratories Ltd.
  • Gufic Biosciences
  • Gland Pharma
Quarterly Results
  • Caplin Point Laboratories Ltd.
  • Gufic Biosciences
  • Gland Pharma
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Caplin Point Laboratories Ltd. Financials

Balance sheet of Caplin Point Lab is strong.
It shouldn't have solvency or liquidity issues.

Yes, The debt of Caplin Point Lab is increasing.
Latest debt of Caplin Point Lab is -₹533.58 Crs as of Sep-24.
This is greater than Mar-24 when it was -₹1,105.06 Crs.

Yes, profit is increasing.
The profit of Caplin Point Lab is ₹517 Crs for TTM, ₹457 Crs for Mar 2024 and ₹376 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Caplin Point Lab latest dividend payout ratio is 8.31% and 3yr average dividend payout ratio is 9.17%

Companies resources are allocated to majorly productive assets like Plant & Machinery

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech